EurekAlert! -
8 Sep 2017 06:00
(European Society for Medical Oncology) Pembrolizumab has shown a promising response rate in patients with pretreated metastatic gastric cancer, according to late-breaking results from the KEYNOTE-059 trial presented today at the ESMO 2017 Congress in Madrid.
Share this Article